Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

1,084

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Hepatitis B, Chronic
Interventions
DRUG

PEGylated recombinant human interferon alpha-2b injection

Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.

DRUG

PEGylated recombinant human interferon alpha-2b injection

Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.

Trial Locations (1)

23000

RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
collaborator

The First Affiliated Hospital, University of Science and Technology of China

OTHER

collaborator

The Second Hospital of Anhui Medical University

OTHER

collaborator

Chaohu Hospital of Anhui Medical University

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

lead

Anhui Medical University

OTHER